Bremelanotide, also known as PT-141, is a melanocortin receptor agonist approved by the FDA in 2019 under the brand name Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike flibanserin, it acts by stimulating melanocortin 1 and 4 receptors in the hypothalamus, which modulate sexual arousal through dopamine release. Though its exact mechanism isn’t fully known, it enhances excitatory pathways in sexual response. It is administered at least 45 minutes before sexual activity and improves desire and reduces distress in HSDD.
Hall, K. S. K., & Binik, Y. M. (2020). Principles and practice of sex therapy (6th ed.). The Guilford Press.
Paauw, D. (2024). Newer outpatient therapies and treatments, an issue of Medical Clinics of North America. Elsevier.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about PT-141 by Livewell Pharmaceuticals, consult with your doctor or healthcare professional.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Stahl, S.M., 2020. Prescriber's Guide: Stahl's Essential Psychopharmacology. United Kingdom: Cambridge University Press.
Home
